Amr R. Ibrahim

Assessment of <i>BCR-ABL1</i> Transcript Levels at 3 Months Is the Only Requirement for Predicting Outcome for Patients With Chronic Myeloid Leukemia Treated With Tyrosine Kinase Inhibitors

David Marín, Amr R. Ibrahim, Claire Lucas et al. · Journal of Clinical Oncology · 2011 · 475 citations

Medicine, Hematology, Oncology +13

Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy

Amr R. Ibrahim, Lina Eliasson, Jane F. Apperley et al. · Blood · 2011 · 316 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +7

Responses to second-line tyrosine kinase inhibitors are durable: an intention-to-treat analysis in chronic myeloid leukemia patients

Dragana Milojković, Jane F. Apperley, Gareth Gerrard et al. · Blood · 2011 · 75 citations · Full text

Medicine, Oncology, Pharmacology +10

Efficacy of tyrosine kinase inhibitors (TKIs) as third-line therapy in patients with chronic myeloid leukemia in chronic phase who have failed 2 prior lines of TKI therapy

Amr R. Ibrahim, Christos Paliompeis, Marco Bua et al. · Blood · 2010 · 72 citations · Full text

Medicine, Oncology, Pharmacology +12

Poor Adherence Is the Main Reason for Loss of CCyR and Imatinib Failure for CML Patients On Long Term Imatinib Therapy.

Amr R. Ibrahim, Dragana Milojković, Marco Bua et al. · Blood · 2010 · 22 citations

Pharmacy, Pharmacotherapy, Immunotherapy +4